Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Adult Participants Living With Elevated Liver Fat and Obesity or Overweight
NCT07441252Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Mar 2026
- Primary completion
- Aug 2027
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of maridebart cafraglutide in obesity, Overweight, metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Amgen. Started Mar 2026; status: active, not recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesityOverweightmetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07441252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441252.